Background and Aim: The incidence of hepatocellular carcinoma (HCC ... occurs among a population chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV).

HBV）肝硬化患者发生肝细胞癌（Hepatocellular carcinoma，HCC）的直接影响尚不清楚。近期，发表于Clinical Gastroenterology and Hepatology（IF：11.6）的研究对此 ...

乙型肝炎病毒（Hepatitis B virus,HBV）感染是重要的公共卫生问题，估计全球流行率为3.8%，影响全球约2.96亿人。慢性乙型肝炎（chronic hepatitis ...

The following is a summary of “Cobalt chloride-mimicked hepatocyte cell hypoxia induces TREX1 leading to Hepatitis B virus ...

This study identifies sociodemographic and health factors predictive of developing HCC among a cohort of people with chronic HBV or HCV infection ... Institute for Cancer Research Health Services ...

Hepatitis B virus (HBV) infection contributes to hepatocellular carcinoma (HCC) tumorigenesis, drug resistance, and recurrence, although the underlying molecular mechanisms remain unclear.

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Hepatocellular Carcinoma.

HBV remains a major global health burden, affecting over 250 million people worldwide. It is a leading cause of liver cancer, responsible for 50%–80% of hepatocellular carcinoma cases globally.

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) therapy, SCG101. The therapy ...